Group items tagged

In 2005, Aché acquired Biosintética Farmacêutica. This acquisition is part of Aché?s strategic plan, which was established in 2004, which aims for, amongst other things, sustained growth, leadership of the domestic market, greater capacity for investment in innovation, and strengthening of the product portfolio. The complementary portfolio and cultural similarities of the two companies were the main factors that led to the acquisition of Biosintética. With this integration, Aché now had 250 therapeutic alternatives and the company moved into new segments such as the cardiovascular area and generic medicines, and the expanded its portfolio in the central nervous system, dermatology, respiratory, oncology and generic medicine areas. Why not visit the Genéricos Biosintética website? - www.genericosbiosintetica.com.br

PHARMACEUTICAL INDUSTRY ANALYSIS Brazil has the 11th largest pharmaceutical market globally with annual sales topping US$17bn. Brazil launched a major 10-year biotechnology initiative in 2007 that provides incentives for private-sector R&D and production. There are some 550 pharmaceutical firms in Brazil. Of the top ten companies by sales in 2008, the first six are all foreign multinational drug makers. Sanofi-Aventis (US$1,229mn in sales) and Novartis (US$1,116mn) are clear leaders, followed by Roche (US$735mn), Pfizer (US$666mn) AstraZeneca (US$584mn) and Eli Lilly (US$545mn). Local firms Aché (US$456mn), EMS Sigma Pharma (US$445mn), Eurofarma (US$424mn) and Biosintética (US$382mn) fill the remaining spots. While this shows the strength of innovation for foreign drugmakers, the presence of five local firms highlights strong competition, as well as the growing use of generic drugs in Brazil. Other leading local producers include Aché/Biosintética, Medley and Libbs. From 2009-2014 BMI forecasts a CAGR of 11.63% for patented drug market in US dollar terms. The projected continuation of sales expansions is one of the key reasons that multinational research-based drugmakers continue to invest in Brazil despite generic competition having eroded some market potential since their inception in 2000. Industry association PróGenéricos has estimated that generics will account for 30% of the market by 2010. Investment reportedly totaled around US$400mn between 1999 and 2006, illustrating not only an expansion of capacity, but also the repositioning of product lines in favor of genuine generics. SOURCE: Business Monitor International